{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:53:20Z","timestamp":1759366400530,"version":"build-2065373602"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,22]],"date-time":"2020-03-22T00:00:00Z","timestamp":1584835200000},"content-version":"am","delay-in-days":356,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.revmed.2018.04.015","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T08:56:30Z","timestamp":1526979390000},"page":"246-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Actualit\u00e9s th\u00e9rapeutiques dans les lymphomes non hodgkiniens et le lymphome de Hodgkin"],"prefix":"10.1016","volume":"40","author":[{"given":"C.","family":"Rossi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.N.","family":"Bastie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.revmed.2018.04.015_bib0315","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.revmed.2018.04.015_bib0320","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography Is prognostically Superior to International prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint italian-danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.revmed.2018.04.015_bib0325","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2016.71.3289","article-title":"Late relapse of classical Hodgkin lymphoma: an analysis of the German Hodgkin study group HD7\u00a0to HD12\u00a0trials","volume":"35","author":"Br\u00f6ckelmann","year":"2017","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.revmed.2018.04.015_bib0330","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.revmed.2018.04.015_bib0335","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10\u00a0trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2018.04.015_bib0340","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10\u00a0trial","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.revmed.2018.04.015_bib0345","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10\u00a0years of follow-up of the GHSG HD9\u00a0study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.revmed.2018.04.015_bib0350","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.revmed.2018.04.015_bib0355","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.V126.23.577.577","article-title":"Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: interim analysis of the AHL2011\u00a0Lysa study","volume":"126","author":"Casasnovas","year":"2015","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.revmed.2018.04.015_bib0360","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9980","key":"10.1016\/j.revmed.2018.04.015_bib0365","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3\u00a0trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.revmed.2018.04.015_bib0370","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3324\/haematol.2012.072090","article-title":"Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant","volume":"98","author":"Van Den Neste","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.revmed.2018.04.015_bib0375","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1185\/03007995.2015.1030378","article-title":"Brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data","volume":"31","author":"Bonthapally","year":"2015","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.revmed.2018.04.015_bib0380","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bulcan.2016.11.005","article-title":"New therapy outlooks in Hodgkin lymphoma","volume":"104","author":"Rossi","year":"2017","journal-title":"Bull Cancer"},{"issue":"1","key":"10.1016\/j.revmed.2018.04.015_bib0385","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1182\/blood.V130.Suppl_1.736.736","volume":"130","author":"Fornecker","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2018.04.015_bib0390","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","author":"Connors","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.revmed.2018.04.015_bib0395","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1\u00a0and PD-L2\u00a0genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2018.04.015_bib0400","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1\u00a0blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2018.04.015_bib0405","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin's lymphoma","author":"Herbaux","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.revmed.2018.04.015_bib0410","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2217\/imt-2017-0002","article-title":"Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors","volume":"9","author":"Baues","year":"2017","journal-title":"Immunotherapy"},{"issue":"12","key":"10.1016\/j.revmed.2018.04.015_bib0415","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5\u00a0trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019\u00e9tudes des lymphomes de l\u2019adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"6769","key":"10.1016\/j.revmed.2018.04.015_bib0420","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.revmed.2018.04.015_bib0425","doi-asserted-by":"crossref","first-page":"18036","DOI":"10.18632\/oncotarget.7495","article-title":"Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB\/non-GCB by immunohistochemistry is still a robust and feasible marker","volume":"7","author":"Batlle-L\u00f3pez","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.revmed.2018.04.015_bib0430","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1158\/1078-0432.CCR-15-2305","article-title":"Next-Generation Sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study","volume":"22","author":"Dubois","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.revmed.2018.04.015_bib0435","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-16-1922","article-title":"Biological and clinical relevance of associated genomic alterations in MYD88\u00a0L265P and non-L265P-mutated diffuse large B-cell lymphoma: analysis of 361\u00a0cases","volume":"23","author":"Dubois","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"31","key":"10.1016\/j.revmed.2018.04.015_bib0440","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9806","key":"10.1016\/j.revmed.2018.04.015_bib0445","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3\u00a0trial","volume":"378","author":"R\u00e9cher","year":"2011","journal-title":"Lancet"},{"issue":"9880","key":"10.1016\/j.revmed.2018.04.015_bib0450","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3\u00a0comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2018.04.015_bib0455","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-05-672196","article-title":"Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?","author":"Le Gouill","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2018.04.015_bib0460","first-page":"1","article-title":"Report of the 6th international workshop on PET in lymphoma","author":"Nanni","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.revmed.2018.04.015_bib0465","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","author":"Thieblemont","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.revmed.2018.04.015_bib0470","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80\u00a0years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2\u00a0trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.revmed.2018.04.015_bib0475","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2016.255","article-title":"A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high\/high-intermediate risk diffuse large B-cell lymphoma","volume":"31","author":"Reddy","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.revmed.2018.04.015_bib0480","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/S2352-3026(17)30016-9","article-title":"Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2\u00a0trial","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.revmed.2018.04.015_bib0485","first-page":"192","article-title":"A phase I, open label, multicenter trail of oral azacitidine (CC-486) plus R-CHOP in patients with high-risk, previouly untreated diffuse large B-cell lymphoma, grade 3B follicular lymphoma or transformed lymphoma","volume":"130","author":"Martin","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.revmed.2018.04.015_bib0490","first-page":"340","article-title":"Preliminary safety and efficacy data for combined checkpoint inhibition with ipilimumab and nivolumab as consolidation following autologous stem cell transplantation (ASCT) for high-risk heamtologic malignancies-Cpit-001\u00a0trial","volume":"130","author":"Skarbnik","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2018.04.015_bib0495","first-page":"80","article-title":"Pola-R-CHP: polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, prednisone for patients with previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Tilly","year":"2017","journal-title":"Hematol Onco"},{"issue":"26","key":"10.1016\/j.revmed.2018.04.015_bib0500","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.revmed.2018.04.015_bib0505","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.revmed.2018.04.015_bib0510","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019\u00e9tude des lymphomes folliculaires","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.revmed.2018.04.015_bib0515","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.revmed.2018.04.015_bib0520","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9759","key":"10.1016\/j.revmed.2018.04.015_bib0525","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"9873","key":"10.1016\/j.revmed.2018.04.015_bib0530","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3\u00a0non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.revmed.2018.04.015_bib0535","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.revmed.2018.04.015_bib0540","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2\u00a0study","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.revmed.2018.04.015_bib0545","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1182\/blood.V128.22.1099.1099","article-title":"Rituximab plus lenalidomide versus rituximab monotherapy in untreated follicular lymphoma patients in need of therapy. First analysis of survival endpoints of the randomized phase-2\u00a0trial SAKK","volume":"128","author":"Kimby","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2018.04.015_bib0550","doi-asserted-by":"crossref","first-page":"037","DOI":"10.1002\/hon.2437_36","article-title":"A phase II LYSA study of obinutzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma","volume":"35","author":"Morschhauser","year":"2017","journal-title":"Hemat Oncol"},{"key":"10.1016\/j.revmed.2018.04.015_bib0555","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood.V128.22.1217.1217","article-title":"Ibrutinib as treatment for chemoimmunotherapy-resistant patients with follicualr lymphoma:first results from the open-label, multicenter, phase 2\u00a0DAWN study","volume":"22","author":"Gopal","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2018.04.015_bib0560","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/hon.2437_126","article-title":"A phase IB study evaluating the safety and clinical activity of atezolizumab combined with obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphoma (NHL)","volume":"35","author":"Palomba","year":"2017","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1016\/j.revmed.2018.04.015_bib0565","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I. First-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.revmed.2018.04.015_bib0570","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","article-title":"Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study","volume":"26","author":"Sebban","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.revmed.2018.04.015_bib0575","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3324\/haematol.2010.030320","article-title":"Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000\u00a0study","volume":"96","author":"Le Gouill","year":"2011","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.revmed.2018.04.015_bib0580","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA Trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2018.04.015_bib0585","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10044","key":"10.1016\/j.revmed.2018.04.015_bib0590","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.revmed.2018.04.015_bib0595","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.revmed.2018.04.015_bib0600","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.revmed.2018.04.015_bib0605","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2\u00a0trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.revmed.2018.04.015_bib0610","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"9873","key":"10.1016\/j.revmed.2018.04.015_bib0615","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3\u00a0non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.revmed.2018.04.015_bib0310","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"Rituximab, Bendamustine and low dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: final results of a phase 2\u00a0study from the Fondazione Italiana Linfomi","volume":"4","author":"Visco","year":"2017","journal-title":"Lancet Haematol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866318305216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866318305216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:40:11Z","timestamp":1759336811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866318305216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0248866318305216"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2018.04.015","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualit\u00e9s th\u00e9rapeutiques dans les lymphomes non hodgkiniens et le lymphome de Hodgkin","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2018.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}